Literature DB >> 1358952

A new approach to the management of Broviac catheter infection.

J S Rao1, A O'Meara, T Harvey, F Breatnach.   

Abstract

Infection continues to be a major complication of the use of indwelling venous catheters. In an attempt to avoid removal of the catheter and to minimize the systemic side-effects of antibiotics, the potential value of in-situ treatment of confirmed Broviac catheter infection was assessed in carefully selected patients attending an oncology unit. Fourteen episodes from 11 children were included in the study. A variety of organisms were encountered. Infective episodes were divided into two categories: (a) those occurring in patients with negative peripheral blood cultures and neutrophil count greater than 1.5 x 10(9) l-1 which were treated only by local instillation of heparinized antibiotic 8-hourly for 7-14 days (N = 8); (b) those occurring simultaneously with positive peripheral blood culture (or peripheral blood culture not performed) regardless of neutrophil count, or infection restricted to Broviac catheter but with a neutrophil count of less than 1.5 x 10(9) l-1; these were treated, with one exception, as above with the addition of systemic antibiotics (N = 6). Treatment was successful in 100% of infective episodes with negative cultures achieved between 5 and 12 days. Catheters remained in use a mean of 118 days following treatment of infection. This approach has obvious advantages but requires careful patient selection and monitoring. It prolongs the catheter life, obviates the need for systemic antibiotics for a local infection, and with appropriate instruction to parents and family practitioner, treatment may be administered on an outpatient basis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1358952     DOI: 10.1016/0195-6701(92)90094-3

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  8 in total

1.  Stability of antibiotics used for antibiotic-lock treatment of infections of implantable venous devices (ports).

Authors:  T U Anthony; L G Rubin
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

2.  Factors associated with recurrence of catheter-related bloodstream infections in home parenteral nutrition patients.

Authors:  G Béraud; D Seguy; S Alfandari; X Lenne; F Leburgue; K Faure; B Guery
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-05-30       Impact factor: 3.267

3.  Vancomycin and ceftazidime bioactivities persist for at least 2 weeks in the lumen in ports: simplifying treatment of port-associated bloodstream infections by using the antibiotic lock technique.

Authors:  Y Haimi-Cohen; N Husain; J Meenan; G Karayalcin; M Lehrer; L G Rubin
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

4.  Optimal antimicrobial catheter lock solution, using different combinations of minocycline, EDTA, and 25-percent ethanol, rapidly eradicates organisms embedded in biofilm.

Authors:  Issam Raad; Hend Hanna; Tanya Dvorak; Gassan Chaiban; Ray Hachem
Journal:  Antimicrob Agents Chemother       Date:  2006-10-30       Impact factor: 5.191

5.  Implantable venous port-related infections in cancer patients.

Authors:  Wen-Tsung Huang; Tsai-Yun Chen; Wu-Chou Su; Chia-Jui Yen; Chao-Jung Tsao
Journal:  Support Care Cancer       Date:  2004-01-16       Impact factor: 3.603

6.  "In-situ" Teicoplanin for central venous catheter infection.

Authors:  A McCarthy; M Byrne; F Breathnach; A O'Meara
Journal:  Ir J Med Sci       Date:  1995 Apr-Jun       Impact factor: 1.568

Review 7.  Antibiotic lock therapy: review of technique and logistical challenges.

Authors:  Julie Ann Justo; P Brandon Bookstaver
Journal:  Infect Drug Resist       Date:  2014-12-12       Impact factor: 4.003

Review 8.  Access technique and its problems in parenteral nutrition - Guidelines on Parenteral Nutrition, Chapter 9.

Authors:  K W Jauch; W Schregel; Z Stanga; S C Bischoff; P Brass; W Hartl; S Muehlebach; E Pscheidl; P Thul; O Volk
Journal:  Ger Med Sci       Date:  2009-11-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.